Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 14/20 | 0.61 |
| ▸ | MC3R | P41968 | 5/20 | 0.61 |
| ▸ | MC5R | P33032 | 4/20 | 0.56 |
| ▸ | PRCP | P42785 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14065621 | 0.97 | MC4R (0.65) | MC4RMC3RMC5RPRCP | |
| SCHEMBL14065581 | 0.97 | MC4R (0.65) | MC4RMC3RMC5RPRCP | |
| Trifluoroacetic Acid SCHEMBL4840684 | 0.96 | MC4R (0.63) | MC4RMC3RMC5RPRCP | |
| SCHEMBL14065586 | 0.92 | MC4R (0.67) | MC4RMC3RMC5RPRCP | |
| SCHEMBL14065583 | 0.89 | MC4R (0.62) | MC4RMC3RMC5RPRCP | |
| SCHEMBL4832638 | 0.87 | MC4R (0.74) | MC4RMC3RMC5RPRCP | |
| SCHEMBL14065584 | 0.87 | MC4R (0.62) | MC4RMC3RMC5RPRCP | |
| SCHEMBL14065588 | 0.87 | MC4R (0.65) | MC4RMC3RMC5RPRCP | |
| SCHEMBL14065585 | 0.86 | MC4R (0.64) | MC4RMC3RMC5RPRCP | |
| SCHEMBL4844333 | 0.84 | MC4R (0.64) | MC4RMC3RMC5RPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419990-B2 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060128963-A1 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128963-A1 | Piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC1R | MC4R 1/4885MC3R 4/4885MC5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.